Neoadjuvant endocrine therapy in primary breast cancer: indications and use as a research tool (Q34253719)

31 July 2017

1 reference

15 October 2020

Neoadjuvant endocrine therapy in primary breast cancer: indications and use as a research tool (English)

1 reference

hormonal antineoplastic agent

31 July 2017

1 reference

15 October 2020

1 reference

15 October 2020

adjuvant chemotherapy

1 reference

Y H Chia

1

1 reference

31 July 2017

M J Ellis

series ordinal

2

1 reference

31 July 2017

C X Ma

series ordinal

3

1 reference

31 July 2017

language of work or name

English

0 references

publication date

10 August 2010

1 reference

British Journal of Cancer

31 July 2017

7 September 2010

5 references

13 March 2019

3 April 2019

17 June 2019

25 June 2019

15 October 2020

6 references

31 July 2017

13 March 2019

3 April 2019

17 June 2019

25 June 2019

15 October 2020

103

1 reference

31 July 2017

759-764

1 reference

31 July 2017

6

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6605845

31 July 2017

0 references

cites work

A randomised trial of mastectomy only versus tamoxifen for treating elderly patients with operable primary breast cancer-final results at 20-year follow-up

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966629

Genome remodelling in a basal-like breast cancer metastasis and xenograft

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966629

Improved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase inhibitor therapy: results from a multicenter phase II trial

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966629

PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966629

Gene expression profiles differentiating between breast cancers clinically responsive or resistant to letrozole

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966629

Supervised risk predictor of breast cancer based on intrinsic subtypes

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966629

Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966629

Antitumour and biological effects of letrozole and GnRH analogue as primary therapy in premenopausal women with ER and PgR positive locally advanced operable breast cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966629

Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966629

Surgery versus primary endocrine therapy for operable primary breast cancer in elderly women (70 years plus)

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966629

A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966629

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966629

Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966629

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966629

A gene-expression signature as a predictor of survival in breast cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966629

Tamoxifen as initial sole treatment of localised breast cancer in elderly women: a pilot study

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966629

Long-term follow-up of elderly patients with locoregional breast cancer treated with tamoxifen only

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966629

Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer

6 July 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605845

Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605845

Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605845

Estrogen-receptor-directed neoadjuvant therapy for breast cancer: results of a randomised trial using formestane and methotrexate, mitozantrone and mitomycin C (MMM) chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605845

Exemestane as primary systemic treatment for hormone receptor positive post-menopausal breast cancer patients: a phase II trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-17).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605845

Tamoxifen alone versus adjuvant tamoxifen for operable breast cancer of the elderly: long-term results of the phase III randomized controlled multicenter GRETA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605845

Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605845

Meta-analysis of pre-operative aromatase inhibitor versus tamoxifen in postmenopausal woman with hormone receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605845

Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605845

Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605845

Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966629

Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966629

HER2 and Response to Paclitaxel in Node-Positive Breast Cancer

28 October 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605845

Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605845

Should tamoxifen be a primary treatment choice for elderly breast cancer patients with locoregional disease?

21 January 2018

1 reference

12 December 2020

Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) trial

1 reference

12 December 2020

Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole

1 reference

12 December 2020

Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer

1 reference

12 December 2020

The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers

1 reference

12 December 2020

A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer

1 reference

12 December 2020

Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM

1 reference

12 December 2020

Factors predictive of outcome in patients with breast cancer refractory to neoadjuvant chemotherapy

1 reference

12 December 2020

Routine omission of sentinel lymph node biopsy for merkel cell carcinoma <= 1 cm is not justified

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605845

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1038/SJ.BJC.6605845

1 reference

Dimensions Publication ID

31 July 2017

0 references

1 reference

31 July 2017

1 reference